<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAMPATH- alemtuzumab injection </strong><br>Genzyme Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CAMPATH safely and effectively. See full prescribing information for CAMPATH.<br><br>CAMPATH<span class="Sup">®</span>(alemtuzumab)<br>Injection for intravenous use<br>Initial U.S. Approval: 2001<br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">CYTOPENIAS</span>, INFUSION REACTIONS, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> </span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Emphasis"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></span></h1>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Serious, including fatal, <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, infusion reactions and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can occur (</span></span><span class="Bold"><span class="Emphasis"><a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">5.1</a></span></span><span class="Bold"><span class="Emphasis">                                        – </span></span><span class="Bold"><span class="Emphasis"><a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">5.3</a></span></span><span class="Bold"><span class="Emphasis">).</span></span> </p>
<ul>
<li>
<span class="Bold"><span class="Emphasis">Limit doses to 30 mg (single) and 90 mg (cumulative weekly); higher doses increase risk of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (</span></span><span class="Bold"><span class="Emphasis"><a href="#ad47cfad-55a7-4936-9462-2db8c8571b2a">2.1</a></span></span><span class="Bold"><span class="Emphasis">).</span></span>
</li>
<li>
<span class="Bold"><span class="Emphasis">Escalate dose gradually and monitor patients during infusion. Withhold therapy for Grade 3 or 4 infusion reactions (</span></span><span class="Bold"><span class="Emphasis"><a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">5.2</a></span></span><span class="Bold"><span class="Emphasis">).</span></span>
</li>
<li>
<span class="Bold"><span class="Emphasis">Administer prophylaxis against </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">Pneumocystis jiroveci</span></span></span><span class="Bold"><span class="Emphasis"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) and <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span></span></span>                                            (<span class="Bold"><span class="Emphasis"><a href="#c7f2e40f-f47f-426d-9b23-5400460fa97e">2.2</a></span></span><span class="Bold"><span class="Emphasis">, </span></span><span class="Bold"><span class="Emphasis"><a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">5.3</a></span></span><span class="Bold"><span class="Emphasis">).</span></span>
</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">CYTOPENIAS</span>, INFUSION REACTIONS, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> </span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Emphasis"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></span></h1>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Serious, including fatal, <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, infusion reactions and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can occur (</span></span><span class="Bold"><span class="Emphasis"><a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">5.1</a></span></span><span class="Bold"><span class="Emphasis">                                        – </span></span><span class="Bold"><span class="Emphasis"><a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">5.3</a></span></span><span class="Bold"><span class="Emphasis">).</span></span> </p>
<ul>
<li>
<span class="Bold"><span class="Emphasis">Limit doses to 30 mg (single) and 90 mg (cumulative weekly); higher doses increase risk of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (</span></span><span class="Bold"><span class="Emphasis"><a href="#ad47cfad-55a7-4936-9462-2db8c8571b2a">2.1</a></span></span><span class="Bold"><span class="Emphasis">).</span></span>
</li>
<li>
<span class="Bold"><span class="Emphasis">Escalate dose gradually and monitor patients during infusion. Withhold therapy for Grade 3 or 4 infusion reactions (</span></span><span class="Bold"><span class="Emphasis"><a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">5.2</a></span></span><span class="Bold"><span class="Emphasis">).</span></span>
</li>
<li>
<span class="Bold"><span class="Emphasis">Administer prophylaxis against </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">Pneumocystis jiroveci</span></span></span><span class="Bold"><span class="Emphasis"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) and <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span></span></span>                                            (<span class="Bold"><span class="Emphasis"><a href="#c7f2e40f-f47f-426d-9b23-5400460fa97e">2.2</a></span></span><span class="Bold"><span class="Emphasis">, </span></span><span class="Bold"><span class="Emphasis"><a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">5.3</a></span></span><span class="Bold"><span class="Emphasis">).</span></span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Campath is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (B-CLL) (<a href="#ad65b840-a14c-41ff-bc51-c398ea4dfeba">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Administer as an IV infusion over 2 hours (<a href="#ad47cfad-55a7-4936-9462-2db8c8571b2a">2.1</a>).</li>
<li>Escalate to recommended dose of 30 mg/day three times per week for 12 weeks (<a href="#ad47cfad-55a7-4936-9462-2db8c8571b2a">2.1</a>).</li>
<li>Premedicate with oral antihistamine and acetaminophen prior to dosing (<a href="#c7f2e40f-f47f-426d-9b23-5400460fa97e">2.2</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">30 mg/1 mL single use vial (<a href="#d310bbcc-5202-4b8f-8d0d-00689c3d38c5">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#c9f8504b-2018-4271-a1cb-f9c437e3e637">4</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span>: </span></span> </p>
<ul class="Square">
<li>Obtain complete blood counts (CBC) and platelet counts at weekly intervals during therapy and CD4 counts after therapy until recovery to ≥ 200 cells/µL (<a href="#f1be999c-fe5c-411f-a747-7c4c87e7acce">5.4</a>).</li>
<li>Discontinue for autoimmune or severe hematologic adverse reactions (<a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">5.1</a>).</li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: </span></span> </p>
<ul class="Square">
<li>Campath induces severe and prolonged <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> and increases risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs, withhold treatment until <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> resolves (<a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">5.3</a>).</li>
<li>Do not administer live viral vaccines to patients who have recently received Campath (<a href="#cc804d37-e85b-4c8e-9993-7e00eb9c11a2">5.5</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 10%): <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, infusion reactions, cytomegalovirus (CMV) and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (<a href="#c2e18ecf-c3c9-47b1-be70-11f5c6db87b5">6</a>). </p>
<br><p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-877-4-CAMPATH (1-877-422-6728) or FDA at 1-800-FDA-1088 or </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">www.fda.gov/medwatch</span></span></span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">CYTOPENIAS</span>, INFUSION REACTIONS, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Schedule and Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Concomitant Medications</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Modification</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation and Administration</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Incompatibilities</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Infusion Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Laboratory Monitoring</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Immunization</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Immunogenicity</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Previously Untreated B-CLL Patients</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Previously Treated B-CLL Patients</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="bf69cffc-07cc-437e-8d6b-4399438ba659"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">CYTOPENIAS</span>, INFUSION REACTIONS, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h1>
<p class="First"><span class="Bold"><span class="Emphasis"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></span></span></span><span class="Bold"><span class="Emphasis">: Serious, including fatal, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>/<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, autoimmune <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">autoimmune hemolytic anemia</span> can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">[see <a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">WARNINGS AND PRECAUTIONS (5.1)</a>]</span></span></span><span class="Bold"><span class="Emphasis"><span class="Italics">.</span></span></span></p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline">Infusion Reactions</span></span></span><span class="Bold"><span class="Emphasis">: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">[see <a href="#f7b83183-68a7-4528-8d80-5aa66bbd8f2a">DOSAGE AND ADMINISTRATION (2)</a> and </span></span></span><span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">WARNINGS AND PRECAUTIONS (5.2)</a>]</span></span></span>.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></span><span class="Bold"><span class="Emphasis">: Serious, including fatal, bacterial, viral, fungal, and protozoan <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can occur in patients receiving Campath. Administer prophylaxis against </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">Pneumocystis jiroveci</span></span></span><span class="Bold"><span class="Emphasis"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) and <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span> </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">[see <a href="#c7f2e40f-f47f-426d-9b23-5400460fa97e">DOSAGE AND ADMINISTRATION (2.2)</a> and </span></span></span><span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a>]</span></span></span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ad65b840-a14c-41ff-bc51-c398ea4dfeba"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Campath is indicated as a single agent for the treatment of B-cell <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (B-CLL).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f7b83183-68a7-4528-8d80-5aa66bbd8f2a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="ad47cfad-55a7-4936-9462-2db8c8571b2a"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Schedule and Administration</h2>
<ul>
<li>Administer as an IV infusion over 2 hours.<span class="Bold"><span class="Emphasis"> Do not administer as intravenous push or bolus.</span></span>
</li>
<li>Recommended Dosing Regimen <ul>
<li>Gradually escalate to the maximum recommended single dose of 30 mg. Escalation is required at initiation of dosing or if dosing is held ≥ 7 days during treatment. Escalation to 30 mg ordinarily can be accomplished in 3 - 7 days.</li>
<li>Escalation Strategy: <ul class="Circle">
<li>Administer 3 mg daily until infusion reactions are ≤ grade 2 <span class="Italics"><span class="Emphasis">[see<a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0"> ADVERSE REACTIONS (6.1)</a>]</span></span>.</li>
<li>Then administer 10 mg daily until infusion reactions are ≤ grade 2.</li>
<li>Then administer 30 mg/day three times per week on alternate days (e.g., Mon-Wed-Fri). The total duration of therapy, including dose escalation, is 12 weeks.</li>
</ul>
</li>
</ul>
</li>
<li><span class="Bold"><span class="Emphasis"> Single doses of greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c7f2e40f-f47f-426d-9b23-5400460fa97e"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Concomitant Medications</h2>
<ul>
<li>Premedicate with diphenhydramine (50 mg) and acetaminophen (500-1000 mg) 30 minutes prior to first infusion and each dose escalation. Institute appropriate medical management (e.g. steroids, epinephrine, meperidine) for infusion reactions as needed<span class="Italics"><span class="Emphasis"> [see <a href="#bf69cffc-07cc-437e-8d6b-4399438ba659">BOXED WARNING</a></span></span>, <span class="Italics"><span class="Emphasis"><a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">WARNINGS AND PRECAUTIONS (5.2)</a> and</span></span><span class="Italics"><span class="Emphasis"><a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0"> ADVERSE REACTIONS (6.1)</a>]</span></span>.</li>
<li>Administer trimethoprim/sulfamethoxazole DS twice daily (BID) three times per week (or equivalent) as <span class="Italics"><span class="Emphasis">Pneumocystis jiroveci</span></span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) prophylaxis.</li>
<li>Administer famciclovir 250 mg BID or equivalent as herpetic prophylaxis.</li>
</ul>
<p class="First">Continue PCP and herpes viral prophylaxis for a minimum of 2 months after completion of Campath or until the CD4+ count is ≥ 200 cells/µL, whichever occurs later <span class="Italics"><span class="Emphasis">[see <a href="#bf69cffc-07cc-437e-8d6b-4399438ba659">BOXED WARNING</a> and </span></span><span class="Italics"><span class="Emphasis"><a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f31ad387-b996-48f7-b99f-5cad2d3308b3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Modification</h2>
<ul>
<li>Withhold Campath during serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or other serious adverse reactions until resolution.</li>
<li>Discontinue Campath for autoimmune <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span>. </li>
<li>There are no dose modifications recommended for <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>.</li>
</ul>
<p class="First"><br></p>
<a name="e4569813-bef6-4451-98ee-aed1c63e392f"></a><table>
<caption><span>Dose Modification for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> [see <a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">                                                    WARNINGS AND PRECAUTIONS (5.1)</a>]</span></caption>
<col width="50%">
<col width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>
<span class="Bold"><span class="Emphasis"></span></span>If the delay between dosing is ≥ 7 days, initiate therapy at Campath 3 mg and escalate to 10 mg and then to 30 mg as tolerated <span class="Italics"><span class="Emphasis">[see <a href="#ad47cfad-55a7-4936-9462-2db8c8571b2a">                                                                      DOSAGE AND ADMINISTRATION (2.1)</a>].</span></span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Emphasis"><span class="Underline">                                                  Hematologic Values </span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Emphasis"><span class="Underline"> Dose Modification<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>  </span></span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">ANC &lt; 250/μL and/or platelet count ≤25,000/μL</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">For first occurrence:</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Withhold Campath therapy. Resume Campath<br>at 30 mg when ANC ≥ 500/μL and platelet count ≥ 50,000/μL.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">For second occurrence:</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Withhold Campath therapy. Resume Campath<br>at 10 mg when ANC ≥ 500/μL and platelet count ≥ 50,000/μL.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">For third occurrence:</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Discontinue Campath therapy.</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First">≥ 50% decrease from baseline in patients initiating therapy with a baseline ANC ≤ 250/μL and/or a baseline platelet count ≤ 25,000/μL</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">For first occurrence:</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Withhold Campath therapy. Resume Campath<br>at 30 mg upon return to baseline value(s).</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">For second occurrence:</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Withhold Campath therapy. Resume Campath<br>at 10 mg upon return to baseline value(s).</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">For third occurrence:</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Discontinue Campath therapy.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b005ecd0-7dd9-4e10-a8a6-945b1a79dc79"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation and Administration</h2>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If particulate matter is present or the solution is discolored, the vial should not be used. <span class="Bold"><span class="Emphasis">DO NOT SHAKE VIAL</span></span>.</p>
<p>Use aseptic technique during the preparation and administration of Campath. Withdraw the necessary amount of Campath from the vial into a syringe.</p>
<ul>
<li>To prepare the 3 mg dose, withdraw 0.1 mL into a 1 mL syringe calibrated in increments of 0.01 mL.</li>
<li>To prepare the 10 mg dose, withdraw 0.33 mL into a 1 mL syringe calibrated in increments of 0.01 mL.</li>
<li>To prepare the 30 mg dose, withdraw 1 mL in either a 1 mL or 3 mL syringe calibrated in 0.1 mL increments.</li>
</ul>
<p>Inject syringe contents into 100 mL sterile 0.9% Sodium Chloride USP or 5% Dextrose in Water USP. <span class="Bold"><span class="Emphasis"><span class="Underline">Gently invert the bag to mix the solution.</span></span></span> Discard syringe.</p>
<p><span class="Bold"><span class="Emphasis"> The vial contains no preservatives and is intended for single use only.  DISCARD VIAL including any unused portion after withdrawal of dose. </span></span></p>
<p>Use within 8 hours after dilution. Store diluted Campath at room temperature (15-30°C) or refrigerated (2-8°C).  Protect from light.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="eb44d956-a74f-41f4-b2b1-4ffb6f8d4a87"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Incompatibilities</h2>
<p class="First">Campath is compatible with polyvinylchloride (PVC) bags and PVC or polyethylene-lined PVC administration sets. Do not add or simultaneously infuse other drug substances through the same intravenous line.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="d310bbcc-5202-4b8f-8d0d-00689c3d38c5"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">30 mg/1 mL single use vial</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="c9f8504b-2018-4271-a1cb-f9c437e3e637"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="bb4bd42b-a5f2-4474-b9e4-583f3c9b241e"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="fef77c43-fb72-475a-80a5-6e0f9293ed9d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></h2>
<p class="First">Severe, including fatal, autoimmune <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and prolonged <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> have been reported in patients receiving Campath. </p>
<p>In addition, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, and hypoplasia have been reported after treatment with Campath at the recommended dose. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p>Withhold Campath for severe <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> (except <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>).  Discontinue for autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> or recurrent/persistent severe <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> (except <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>)<span class="Italics"><span class="Emphasis">[see <a href="#f31ad387-b996-48f7-b99f-5cad2d3308b3">                                                DOSAGE AND ADMINISTRATION (2.3)</a>]</span></span>. No data exist on the safety of Campath resumption in patients with autoimmune <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> or marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> <span class="Italics"><span class="Emphasis">[see <a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0">                                                ADVERSE REACTIONS (6.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="c59f65eb-c396-4111-89f2-95dfeaa9cd3a"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Infusion Reactions</h2>
<p class="First">Adverse reactions occurring during or shortly after Campath infusion include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.  In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Monitor for the signs and symptoms listed above and withhold infusion for Grade 3 or 4 infusion reactions <span class="Italics"><span class="Emphasis">[see <a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0">ADVERSE REACTIONS (6.1)</a>]</span></span>.</p>
<p>The following serious, including fatal, infusion reactions have been identified in post-marketing reports: <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="442310" conceptname="Acute heart failure">acute cardiac insufficiency</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid shock</span>.</p>
<p>Initiate Campath according to the recommended dose-escalation scheme 										<span class="Emphasis"><span class="Italics">[</span>see <span class="Italics"><a href="#f7b83183-68a7-4528-8d80-5aa66bbd8f2a">DOSAGE AND ADMINISTRATION (2)</a>]</span></span>. Premedicate patients with an antihistamine and acetaminophen prior to dosing. Institute medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion reactions as needed <span class="Italics"><span class="Emphasis">[</span></span><span class="Italics"><span class="Emphasis">see <a href="#c7f2e40f-f47f-426d-9b23-5400460fa97e">DOSAGE AND ADMINISTRATION (2.2)</a>]</span></span>. If therapy is interrupted for 7 or more days, reinstitute Campath with gradual dose escalation <span class="Italics"><span class="Emphasis">[see <a href="#f31ad387-b996-48f7-b99f-5cad2d3308b3">DOSAGE AND ADMINISTRATION (2.3)</a></span></span> and <span class="Italics"><span class="Emphasis"><a href="#c2e18ecf-c3c9-47b1-be70-11f5c6db87b5">ADVERSE REACTIONS (6)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="e9cadbb3-3325-4a38-ab17-0b68caa2b65e"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Campath treatment results in severe and prolonged <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> with a concomitant increased incidence of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> <span class="Italics"><span class="Emphasis">[see<a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0"> ADVERSE REACTIONS (6.1)</a>]</span></span>. Administer PCP and herpes viral prophylaxis during Campath therapy and for a minimum of 2 months after completion of Campath or until the CD4+ count is ≥ 200 cells/µL, whichever occurs later <span class="Italics"><span class="Emphasis">[see<a href="#c7f2e40f-f47f-426d-9b23-5400460fa97e"> DOSAGE AND ADMINISTRATION (2.2)</a>]</span></span>. Prophylaxis does not eliminate these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Routinely monitor patients for <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> during Campath treatment and for at least 2 months following completion of treatment. Withhold Campath for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and during antiviral treatment for <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> or confirmed <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> (defined as <span class="product-label-link" type="condition" conceptid="4120014" conceptname="Polymerase chain reaction">polymerase chain reaction</span> (PCR) positive CMV in ≥ 2 consecutive samples obtained 1 week apart) <span class="Italics"><span class="Emphasis">[see<a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0"> ADVERSE REACTIONS (6.1)</a>]</span></span>. Initiate therapeutic ganciclovir (or equivalent) for <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> or confirmed <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> <span class="Italics"><span class="Emphasis">[see<a href="#f31ad387-b996-48f7-b99f-5cad2d3308b3"> DOSAGE AND ADMINISTRATION (2.3)</a>]</span></span>.</p>
<p>Administer only irradiated blood products to avoid transfusion associated <span class="product-label-link" type="condition" conceptid="443216" conceptname="Graft versus host disease">Graft versus Host Disease</span> (TAGVHD), unless emergent circumstances dictate immediate transfusion.<span class="Sup">1</span></p>
<p>In patients receiving Campath as initial therapy, recovery of CD4+ counts to ≥ 200 cells/µL occurred by 6 months post-treatment; however at 2 months post-treatment, the median was 183 cells/µL. In previously treated patients receiving Campath, the median time to recovery of CD4+ counts to ≥ 200 cells/µL was 2 months; however, full recovery (to baseline) of CD4+ and CD8+ counts may take more than 12 months <span class="Italics"><span class="Emphasis">[see <a href="#bf69cffc-07cc-437e-8d6b-4399438ba659">BOXED WARNING</a> and </span></span><span class="Italics"><span class="Emphasis"><a href="#c2e18ecf-c3c9-47b1-be70-11f5c6db87b5">ADVERSE REACTIONS (6)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f1be999c-fe5c-411f-a747-7c4c87e7acce"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Laboratory Monitoring</h2>
<p class="First">Obtain complete blood counts (CBC) at weekly intervals during Campath therapy and more frequently if worsening <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> occurs. Assess CD4+ counts after treatment until recovery to ≥ 200 cells/µL <span class="Italics"><span class="Emphasis">[see <a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a> and </span></span><span class="Italics"><span class="Emphasis"><a href="#c2e18ecf-c3c9-47b1-be70-11f5c6db87b5">ADVERSE REACTIONS (6)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="cc804d37-e85b-4c8e-9993-7e00eb9c11a2"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Immunization</h2>
<p class="First">The safety of immunization with live viral vaccines following Campath therapy has not been studied. Do not administer live viral vaccines to patients who have recently received Campath. The ability to generate an immune response to any vaccine following Campath therapy has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="c2e18ecf-c3c9-47b1-be70-11f5c6db87b5"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span> <span class="Italics"><span class="Emphasis">[see <a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">WARNINGS AND PRECAUTIONS (5.1)</a>]</span></span>
</li>
<li>Infusion Reactions<span class="Italics"><span class="Emphasis">[see <a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">WARNINGS AND PRECAUTIONS (5.2)</a>]</span></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> <span class="Italics"><span class="Emphasis">[see <a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a>]</span></span>
</li>
</ul>
<p>The most common adverse reactions with Campath are: infusion reactions (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>), <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span>, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>, other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>), <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), and neurological symptoms (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>). The most common serious adverse reactions are <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, infusion reactions, and <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="f570f7cb-c2e1-471b-8746-b07dc34052f0"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data below reflect exposure to Campath in 296 patients with CLL of whom 147 were previously untreated and 149 received at least 2 prior chemotherapy regimens. The median duration of exposure was 11.7 weeks for previously untreated patients and 8 weeks for previously treated patients.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span>: </span></span>Severe <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> and a rapid and sustained decrease in lymphocyte subsets occurred in previously untreated and previously treated patients following administration of Campath. In previously untreated patients, the median CD4+ was 0 cells/μL at one month after treatment and 238 cells/μL [25-75% interquartile range 115 to 418 cells/μL at 6 months post-treatment <span class="Italics"><span class="Emphasis">[see <a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a>]</span></span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: </span></span>In previously untreated patients, the incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was 42% with a median time to onset of 31 days and a median duration of 37 days. In previously treated patients, the incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was 64% with a median duration of 28 days. Ten percent of previously untreated patients and 17% of previously treated patients received granulocyte colony stimulating factors.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: </span></span>In previously untreated patients, the incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was 12% with a median time to onset of 31 days and a median duration of 8 days. In previously treated patients, the incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was 38%. Seventeen percent of previously untreated patients and 66% of previously treated patients received either erythropoiesis stimulating agents, transfusions or both.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: </span></span>In previously untreated patients, the incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was 14% with a median time to onset of 9 days and a median duration of 14 days. In previously treated patients, the incidence of Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was 52% with a median duration of 21 days. <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">Autoimmune thrombocytopenia</span> was reported in 2% of previously treated patients with one fatality.</p>
<p><span class="Italics"><span class="Emphasis">Infusion reactions: </span></span>Infusion reactions, which included <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, were common. Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> occurred in approximately 10% of previously untreated patients and in approximately 35% of previously treated patients. The occurrence of infusion reactions was greatest during the initial week of treatment and decreased with subsequent doses of Campath. All patients were pretreated with antipyretics and antihistamines; additionally, 43% of previously untreated patients received glucocorticoid pre-treatment.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: </span></span>In the study of previously untreated patients, patients were tested weekly for CMV using a PCR assay from initiation through completion of therapy, and every 2 weeks for the first 2 months following therapy. <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> occurred in 16% (23/147) of previously untreated patients; approximately one-third of these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were serious or life threatening. In studies of previously treated patients in which routine CMV surveillance was not required, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> was documented in 6% (9/149) of patients; nearly all of these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were serious or life threatening.</p>
<p>Other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported in approximately 50% of patients across all studies. Grade 3 - 5 <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> ranged from 3% to 10% across studies and was higher in previously treated patients. Grade 3 - 4 <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> ranged from 5 to 10% across studies and was higher in previously treated patients. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>-related fatalities occurred in 2% of previously untreated patients and 16% of previously treated patients. There were 198 episodes of other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in 109 previously untreated patients; 16% were bacterial, 7% were fungal, 4% were other viral, and in 73%, the organism was not identified.</p>
<p><span class="Italics"><span class="Emphasis">Cardiac: </span></span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac dysrhythmias</span> occurred in approximately 14% of previously untreated patients. The majority were <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardias</span> and were temporally associated with infusion; <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> were Grade 3 or 4 in 1% of patients.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Underline">Previously Untreated Patients </span></span></span></p>
<p><a href="#ceb347e2-c500-458f-81d8-6d1fc41dfc83">Table 1</a> contains selected adverse reactions observed in 294 patients randomized (1:1) to receive Campath or chlorambucil as first line therapy for B-CLL. Campath was administered at a dose of 30 mg intravenously three times weekly for up to 12 weeks. The median duration of therapy was 11.7 weeks with a median weekly dose of 82 mg (25-75% interquartile range: 69 mg – 90 mg).</p>
<br><a name="ceb347e2-c500-458f-81d8-6d1fc41dfc83"></a><table>
<caption><span>Table 1</span></caption>
<thead class="Botrule Lrule Rrule Toprule">
<tr><th class="Botrule Lrule Rrule Toprule" align="center" colspan="6"><span class="Bold"><span class="Emphasis">Per Patient Incidence of Selected<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> Adverse Reactions in Treatment Naive B-CLL Patients</span></span></th></tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="2"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Campath (n=147)</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2">Chlorambucil (n=147)</th>
</tr>
</thead>
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>
<span class="Bold"><span class="Emphasis"></span></span> Adverse reactions occurring at a higher relative frequency in the Campath arm</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>
<span class="Bold"><span class="Emphasis"></span></span>   NCI CTC version 2.0 for adverse reactions; NCI CTCAE version 3.0 for laboratory values</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>   <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> (without evidence of symptoms) includes both cases of single PCR positive test results and of confirmed <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> (≥ 2 occasions in consecutive samples 1 week apart).  For the latter, ganciclovir (or equivalent) was initiated per protocol.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2">  </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">All Grades<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>    </span></span><br><span class="Bold"><span class="Emphasis">%</span></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Emphasis">Grades 3-4 <br></span></span><span class="Bold"><span class="Emphasis">%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">All Grades<br>% </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="Emphasis">Grades<br>3-4<br></span></span><span class="Bold"><span class="Emphasis">%</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" rowspan="4">Blood and Lymphatic System Disorders</td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">97</td>
<td class="Botrule Lrule Rrule Toprule" align="center">97</td>
<td class="Botrule Lrule Rrule Toprule" align="center">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">77</td>
<td class="Botrule Lrule Rrule Toprule" align="center">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center">51</td>
<td class="Botrule Lrule Rrule Toprule" align="center">26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">76</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center">54</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">71</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center">70</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2">General Disorders and Administration Site Conditions</td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">69</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">53</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>    </td>
<td class="Botrule Lrule Rrule Toprule" align="center">55</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">74</td>
<td class="Botrule Lrule Rrule Toprule" align="center">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center">65</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3">Skin and Subcutaneous Tissue Disorders</td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2">Psychiatric Disorders</td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Emphasis"><span class="Underline">Previously Treated Patients </span></span></span></p>
<p>Additional safety information was obtained from 3 single arm studies of 149 previously treated patients with CLL administered 30 mg Campath intravenously three times weekly for 4 to 12 weeks (median cumulative dose 673 mg [range 2 – 1106 mg]; median duration of therapy 8.0 weeks). Adverse reactions in these studies not listed in <a href="#ceb347e2-c500-458f-81d8-6d1fc41dfc83">Table 1</a> that occurred at an incidence rate of &gt; 5% were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="cabd3882-92fb-4b2b-b532-4ec2027c137e"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is potential for immunogenicity. Using an ELISA assay, anti-human antibodies (HAHA) were detected in 11 of 133 (8.3%) previously untreated patients. In addition, two patients were weakly positive for neutralizing activity. Limited data suggest that the anti-Campath antibodies did not adversely affect tumor response. Four of 211 (1.9%) previously-treated patients were found to have antibodies to Campath following treatment.</p>
<p>The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Campath with the incidence of antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="fa4879af-bcae-46a2-bbdf-7d8a0a469e30"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions were identified during post-approval use of Campath. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Campath exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) reported frequency of the reaction, or (3) strength of causal connection to Campath.</p>
<p>Fatal infusion reactions: <span class="Italics"><span class="Emphasis">[see <a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">WARNINGS AND PRECAUTIONS (5.2)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span>.</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>,<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, decreased <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (some patients had been previously treated with cardiotoxic agents).</p>
<p>Immune disorders: Goodpasture's syndrome, Graves' disease, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, fatal transfusion associated <span class="product-label-link" type="condition" conceptid="443216" conceptname="Graft versus host disease">Graft versus Host Disease</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Epstein-Barr Virus (EBV) including EBV-associated <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span>, <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), re-activation of latent viruses.</p>
<p>Metabolic: <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span></p>
<p>Neurologic: <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">optic neuropathy</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="b6d450d5-c8a0-4e69-8da7-66129e439079"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No formal drug interaction studies have been performed with Campath.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="d172d3d3-21f6-4de2-97b9-651f189f69f4"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="b742c4de-5185-4fba-804f-d4cdddda1eca"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Emphasis"> Pregnancy Category C</span></span></p>
<p>Animal reproduction studies have not been conducted with Campath. IgG antibodies, such as Campath, can cross the placental barrier. It is not known whether Campath can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Campath should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="beefe757-ea08-42f1-b40b-f2ea5633ddf2"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Excretion of Campath in human breast milk has not been studied; it is not known whether this drug is excreted in human milk. IgG antibodies, such as Campath, can be excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Campath, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the elimination half-life of Campath and the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="a711f8b3-5a14-4c6d-93d6-2517797dd477"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="e6a8dc76-1fb7-467e-8a3c-8d6430aaaf9f"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of 147 previously untreated B-CLL patients treated with Campath, 35% were ≥ age 65 and 4% were ≥ age 75. Of 149 previously treated patients with B-CLL, 44% were ≥ 65 years of age and 10% were ≥ 75 years of age. Clinical studies of Campath did not include sufficient number of subjects age 65 and over to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="adaa07c7-73ca-43ee-9687-cf26d320b002"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Across all clinical experience, the reported maximum single dose received was 90 mg. Bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or severe infusions reactions occurred in patients who received a dose higher than recommended.</p>
<p>One patient received an 80 mg dose by IV infusion and experienced acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, followed by <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Another patient received two 90 mg doses by IV infusion one day apart during the second week of treatment and experienced a rapid onset of bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>.</p>
<p>There is no known specific antidote for Campath overdosage. Treatment consists of drug discontinuation and supportive therapy.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a3937ea8-5120-48f8-ba20-f1c6ffddd869"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Campath (alemtuzumab) is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) directed against the 21-28 kD cell surface glycoprotein, CD52. Campath-1H is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). The Campath-1H antibody has an approximate molecular weight of 150 kD. Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product.</p>
<p>Campath is a sterile, clear, colorless, isotonic solution (pH 6.8-7.4) for injection. Each single use vial of Campath contains 30 mg alemtuzumab, 8.0 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate. No preservatives are added.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a7d646fe-2e8c-4aba-8e9e-66392059b8e7"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="af25e8d7-1072-4967-96e6-27581c832f58"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Campath binds to CD52, an antigen present on the surface of B and T <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34<span class="Sup">+</span> cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of Campath to the leukemic cells.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="bd09f94a-de0e-4369-b6bb-1807baea6ff0"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Emphasis">Cardiac Electrophysiology</span></span></p>
<p>The effect of multiple doses of alemtuzumab (12 mg/day for 5 days) on the QTc interval was evaluated in a single-arm study in 53 patients without malignancy. No large changes in the mean QTc interval (i.e., &gt; 20 ms) were detected in the study. A mean increase in heart rate of 22 to 26 beats/min was observed for at least 2 hours following the initial infusion of alemtuzumab. This increase in heart rate was not observed with subsequent doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="b01464f3-4d8c-4163-bbc1-fe2464bb006a"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Campath pharmacokinetics were characterized in a study of 30 previously treated B-CLL patients in whom Campath was administered at the recommended dose and schedule. Campath pharmacokinetics displayed nonlinear elimination kinetics. After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg). Systemic clearance decreased with repeated administration due to decreased receptor-mediated clearance (i.e., loss of CD52 receptors in the periphery). After 12 weeks of dosing, patients exhibited a seven-fold increase in mean AUC. Mean half-life was 11 hours (range 2 to 32 hours) after the first 30 mg dose and was 6 days (range 1 to 14 days) after the last 30 mg dose.</p>
<p>Comparisons of AUC in patients ≥ 65 years (n=6) versus patients &lt; 65 years (n=15) suggested that no dose adjustments are necessary for age. Comparisons of AUC in female patients (n=4) versus male patients (n=17) suggested that no dose adjustments are necessary for gender.</p>
<p>The pharmacokinetics of Campath in pediatric patients have not been studied. The effects of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of Campath have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ce0f1451-ff90-47d2-bf95-f11156234efc"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ed785c49-716e-457e-9fc5-ff5e13f390bb"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to establish the carcinogenic or mutagenic potential of Campath, or to determine its effects on fertility in males or females.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="e469388f-b30c-43fe-93c5-075b31d6b64c"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="c88a6916-bc32-47b4-83c6-0ceaccbffd51"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Previously Untreated B-CLL Patients</h2>
<p class="First">Campath was evaluated in an open-label, randomized (1:1) active-controlled study in previously untreated patients with B-CLL, Rai Stage I-IV, with evidence of progressive disease requiring therapy. Patients received either Campath 30 mg IV 3 times/week for a maximum of 12 weeks or chlorambucil 40 mg/m<span class="Sup">2 </span>PO once every 28 days, for a maximum of 12 cycles.</p>
<p>Of the 297 patients randomized, the median age was 60 years, 72% were male, 99% were Caucasian, 96% had a WHO performance status 0-1, 23% had maximum lymph node diameter ≥ 5cm, 34% were Rai Stage III/IV, and 8% were treated in the U.S.</p>
<p>Patients randomized to receive Campath experienced longer progression free survival (PFS) compared to those randomized to receive chlorambucil (median PFS 14.6 months vs. 11.7 months, respectively). The overall response rates were 83% and 55% (p &lt; 0.0001) and the complete response rates were 24% and 2% (p &lt; 0.0001) for Campath and chlorambucil arms, respectively. The Kaplan-Meier curve for PFS is shown in <a href="#bd0486ec-a5a6-40fe-9339-125243f5bcba">Figure 1</a>.</p>
<p>                                                                                                                           <span class="Bold"><span class="Emphasis">Figure </span></span><span class="Bold"><span class="Emphasis">1<br></span></span>                                                             <span class="Bold"><span class="Emphasis">Progression Free Survival in Previously Untreated B-CLL Patients<a name="footnote-reference-5" href="#footnote-5" class="Sup">1</a>  </span></span></p>
<p><img alt="Progression Free Survival in Previously Untreated B-CLL                                         Patients" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4f5f7255-7abc-4328-bd1a-ceaf139ef3e0&amp;name=campath-figure-1.jpg"></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">1</a></dt>
<dd>
<span class="Bold"><span class="Emphasis"></span></span>Log-rank test adjusted for Rai Stage (I-II vs. III-IV).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="dcc4df60-e1d9-4398-a473-dafe25faf722"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Previously Treated B-CLL Patients</h2>
<p class="First">Campath was evaluated in three multicenter, open-label, single arm studies of 149 patients with B-CLL previously treated with alkylating agents, fludarabine, or other chemotherapies. Patients were treated with the recommended dose of Campath, 30 mg intravenously, three times per week for up to 12 weeks. Partial response rates of 21 to 31% and complete response rates of 0 to 2% were observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="d5101b0a-c19c-42fb-b45b-ffd7f17762d6"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First"><span class="Sup">1</span> American Association of Blood Banks, America's Blood Centers, American Red Cross. Circular of Information for the Use of Human Blood and Blood Components. July 2002.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a6040dee-c4c8-4963-a126-a2dc687e958f"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Campath (alemtuzumab) is supplied in single-use clear glass vials containing 30 mg of alemtuzumab in 1 mL of solution. Each carton contains three Campath vials (NDC 58468-0357-3) or one Campath vial (NDC 58468-0357-1).</p>
<p>Store Campath at 2-8°C (36-46°F). Do not freeze. If accidentally frozen, thaw at 2-8°C before administration. Protect from direct sunlight.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="edbaf006-d77f-4261-8e5b-08463ffa534d"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenias</span></span></span>: Advise patients to report any signs or symptoms such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> or <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> <span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#fef77c43-fb72-475a-80a5-6e0f9293ed9d">WARNINGS AND PRECAUTIONS (5.1)</a></span></span><span class="Italics"><span class="Emphasis"> and</span></span> <span class="Italics"><span class="Emphasis"><a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0">ADVERSE REACTIONS (6.1)</a>]</span></span>.</p>
<p><span class="Italics"><span class="Emphasis">Infusion Reactions</span></span>: Advise patients of the signs and symptoms of infusion reactions and of the need to take premedications as prescribed <span class="Italics"><span class="Emphasis">[see <a href="#c59f65eb-c396-4111-89f2-95dfeaa9cd3a">WARNINGS AND PRECAUTIONS (5.2)</a></span></span><span class="Italics"><span class="Emphasis"> and </span></span><span class="Italics"><span class="Emphasis"><a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0">OVERALL ADVERSE REACTIONS (6.1)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: </span></span>Advise patients to immediately report symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>) and to take <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> anti-infectives for PCP (trimethoprim/sulfamethoxazole DS or equivalent) and for herpes virus (famciclovir or equivalent) as prescribed <span class="Italics"><span class="Emphasis">[see <a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a> and </span></span><span class="Italics"><span class="Emphasis"><a href="#f570f7cb-c2e1-471b-8746-b07dc34052f0">ADVERSE REACTIONS (6.1)</a>]</span></span>.</p>
<p>Advise patients that irradiation of blood products is required <span class="Italics"><span class="Emphasis">[see <a href="#e9cadbb3-3325-4a38-ab17-0b68caa2b65e">WARNINGS AND PRECAUTIONS (5.3)</a>]</span></span>.</p>
<p>Advise patients that they should not be immunized with live viral vaccines if they have recently been treated with Campath <span class="Italics"><span class="Emphasis">[see <a href="#cc804d37-e85b-4c8e-9993-7e00eb9c11a2">WARNINGS AND PRECAUTIONS (5.5)</a>]</span></span>.</p>
<p>Advise male and female patients with reproductive potential to use effective contraceptive methods during treatment and for a minimum of 6 months following Campath therapy <span class="Italics"><span class="Emphasis">[see <a href="#ed785c49-716e-457e-9fc5-ff5e13f390bb">NONCLINICAL TOXICOLOGY (13.1)</a>]</span></span>.</p>
<p>Manufactured and distributed by: Genzyme Corporation, Cambridge, MA 02142</p>
<p>Campath is a registered trademark of Genzyme Corporation.</p>
<p>© 2014 Genzyme Corporation.</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d0d2e68e-73cc-483d-92b6-9994162d4b37"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Package Label – Principal Display Panel – 1-Pack Carton</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC 58468-0357-1<br>1 Single-Use 1 mL Vial</span></span></p>
<br><p><span class="Bold"><span class="Emphasis">Campath<br>alemtuzumab</span></span><br>For <span class="Bold"><span class="Emphasis">I</span></span>ntravenous Use Only<br><span class="Bold"><span class="Emphasis">30 mg/mL</span></span></p>
<br><p>- 30 mg/mL<br>- 1 vial<br>- Injection</p>
<p><span class="Bold"><span class="Emphasis">30 mg/mL<br></span></span>No US Standard of Potency<br>Must be further diluted prior to IV administration<br>Single-Use Vial, Discard Unused Portion<br>See package insert for full prescribing information<br>Sterile</p>
<br><p><span class="Bold"><span class="Emphasis">Rx Only</span></span></p>
<br><p><span class="Bold"><span class="Emphasis"><span class="Italics">Note: Concentration change to 30 mg/mL</span></span></span><br><span class="Italics"><span class="Emphasis">See revised insert for new instructions for preparation and administration.</span></span></p>
<br><br><p><img alt="Package Label - Principal Display Panel - 1-Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4f5f7255-7abc-4328-bd1a-ceaf139ef3e0&amp;name=campath-figure-2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="a0b2e68e-73d3-483e-92b6-9994162d4b38"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Package Label – Principal Display Panel – 3-Pack Carton</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC 58468-0357-3<br>3 Single-Use 1 mL Vial</span></span></p>
<br><p><span class="Bold"><span class="Emphasis">Campath<br>alemtuzumab</span></span><br>For <span class="Bold"><span class="Emphasis">I</span></span>ntravenous Use Only<br><span class="Bold"><span class="Emphasis">30 mg/mL</span></span></p>
<br><p>- 30 mg/mL<br>- 3 vials<br>- Injection</p>
<br><p><span class="Bold"><span class="Emphasis">30 mg/mL<br></span></span>No US Standard of Potency<br>Must be further diluted prior to IV administration<br>Single-Use Vial, Discard Unused Portion<br>See package insert for full prescribing information<br>Sterile</p>
<br><p><span class="Bold"><span class="Emphasis">Rx Only</span></span></p>
<br><p><span class="Bold"><span class="Emphasis"><span class="Italics">Note: Concentration change to 30 mg/mL</span></span></span><br><span class="Italics"><span class="Emphasis">See revised insert for new instructions for preparation and administration.</span></span></p>
<br><p><img alt="Package Label - Principal Display Panel - 3-Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4f5f7255-7abc-4328-bd1a-ceaf139ef3e0&amp;name=campath-figure-3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAMPATH 		
					</strong><br><span class="contentTableReg">alemtuzumab injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58468-0357</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALEMTUZUMAB</strong> (ALEMTUZUMAB) </td>
<td class="formItem">ALEMTUZUMAB</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">1.44 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem">0.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem">0.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.0187 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58468-0357-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1.0 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:58468-0357-3</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1.0 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103948</td>
<td class="formItem">11/30/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genzyme Corporation
							(025322157)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH &amp; Co. KG (BI Pharma)</td>
<td class="formItem"></td>
<td class="formItem">340700520</td>
<td class="formItem">ANALYSIS(58468-0357), MANUFACTURE(58468-0357), API MANUFACTURE(58468-0357)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Limited</td>
<td class="formItem"></td>
<td class="formItem">229522842</td>
<td class="formItem">MANUFACTURE(58468-0357)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Ireland Limited</td>
<td class="formItem"></td>
<td class="formItem">985127419</td>
<td class="formItem">MANUFACTURE(58468-0357)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d986d7b0-b2f5-48d7-af39-f01669bc674f</div>
<div>Set id: 4f5f7255-7abc-4328-bd1a-ceaf139ef3e0</div>
<div>Version: 6</div>
<div>Effective Time: 20141017</div>
</div>
</div> <div class="DistributorName">Genzyme Corporation</div></p>
</body></html>
